NDAORALTABLET, EXTENDED RELEASE
Approved
Jan 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
3/8 — Basic
TOPROL-XL (metoprolol succinate) by CorMedix is 1 -selective (cardioselective) adrenergic receptor blocking agent. First approved in 1992.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOPROL-XL is an extended-release oral tablet containing metoprolol succinate, a cardioselective beta-1 adrenergic receptor antagonist approved in 1992. It is indicated for hypertension, angina pectoris, and heart failure by reducing cardiac oxygen demand and sympathetic activity. The drug works by competitively blocking catecholamine effects on the heart, lowering heart rate, blood pressure, and myocardial contractility.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team downsizing and shift toward cost-management and generic transition planning.
Mechanism of Action
1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic…
Indications
Worked on TOPROL-XL at CorMedix? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.